GLP-1RA can reduce MACE (major cardiovascular events) and its individual components, CV death, myocardial infarction (MI) and stroke
If intolerable side effects occur during escalation, remain at current dose for an additional 4 weeks before attempting to increase, or drop back to the previous dose
However, the Cleveland Clinic Journal of Medicine 30 positions that the benefits of GLP-1 medications outweigh the risks and until more is known, there's little reason to withhold use unless coming from a personal or family history of medullary or follicular thyroid cancers
These patterns suggest insufficient monitoring and lack of timely dose adjustment following GLP-1RA initiation, potentially leading to thyroid hormone over-replacement
Patients should ensure their practitioner uses CE/UKCA-marked products from reputable manufacturers and has specific experience with the chosen product, particularly for treatments in anatomically complex areas such as the mid-face, temples, and tear troughs
